Projects per year
Personal profile
Interests
Nanomedicine, Antibodies, Antibody-Drug Conjugates (ADCs), cathepsin proteases, cancer, inflammation, infection
Research Statement
Following a primary degree in Biochemistry he undertook a PhD and post doctoral training at Queen’s in molecular enzymology. In 2001, Chris was one of the founding members of QUB spinout company Fusion Antibodies Ltd., before returning to Queen’s in 2003 to take up an academic position. Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Work in his laboratory is funded by agencies such as Medical Research Council, US-Ireland, and various industrial sources such as AstraZeneca and Immunocore. He also held a Royal Society Industrial Fellowship with GSK from 2012-15, and won the Vice Chancellor’s Prize for Innovation in 2015 with his group’s work on developing a novel nanomedicine for the treatment of sepsis and other inflammatory conditions. Chris is a member of the Medical Research Council Developmental Pathway Funding Scheme Panel.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Christopher Scott is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
R1589CNR: Dissecting the role of macrophage-derived cysteine cathepsin S in lung adenocarcinoma
Small, D., Kerr, E., Scott, C. & Williams, R.
06/12/2021 → …
Project: Research
-
-
-
R1248PMY: Evaluation of antibody targeted controlled release nanoparticle systems
01/08/2010 → …
Project: Research
-
Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C-mutant colorectal cancer
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., Lambe, S., Maurya, M., Lindner, A. U., Prehn, J. H. M., Sousa, J., Winnington, C., LaBonte, M. J., Ross, S. & Van Schaeybroeck, S., 01 Jan 2023, In: Molecular Cancer Therapeutics. 22, 1, p. 135–149 15 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Downloads (Pure) -
Multifunctional low temperature-cured PVA/PVP/citric acid-based hydrogel forming microarray patches: physicochemical characteristics and hydrophilic drug interaction
Himawan, A., Anjani, Q. K., Detamornrat, U., Vora, L. K., Permana, A. D., Ghanma, R., Naser, Y., Rahmawanty, D., Scott, C. J. & Donnelly, R. F., 15 Mar 2023, In: European Polymer Journal. 186, 16 p., 111836.Research output: Contribution to journal › Article › peer-review
Open AccessFile17 Downloads (Pure) -
Where microneedle meets biomarkers: futuristic application for diagnosing and monitoring localized external organ diseases
Himawan, A., Vora, L. K., Permana, A. D., Sudir, S., Nurdin, A. R., Nislawati, R., Hasyim, R., Scott, C. J. & Donnelly, R. F., 17 Feb 2023, In: Advanced Healthcare Materials. 12, 5, 33 p., 2202066.Research output: Contribution to journal › Review article › peer-review
Open AccessFile58 Downloads (Pure) -
Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential
Smyth, P., Sasiwachirangkul, J., Williams, R. & Scott, C. J., Dec 2022, In: Molecular Aspects of Medicine. 88, 101106.Research output: Contribution to journal › Article › peer-review
Open AccessFile60 Downloads (Pure) -
Lysosomal cysteine proteases are mediators of cell death in macrophages following exposure to amorphous silica nanoparticles
Ishaq, F., Sereesongsaeng, N., Johnston, M. C., Scott, C. J. & Burden, R. E., 01 Apr 2022, In: Chemico-biological interactions. 356, 109882.Research output: Contribution to journal › Article › peer-review
Activities
-
Medical Research Council (External organisation)
Christopher Scott (Advisor)
Jan 2022Activity: Membership types › Membership of peer review panel or committee
-
Robert STRAUBINGER
Christopher Scott (Host)
Jan 2022 → Jul 2022Activity: Hosting a visitor types › Hosting an academic visitor
-
CSO and scientific co-founder
Christopher Scott (Advisor)
Jan 2022Activity: Consultancy types › KTP & Consultancy in kind
-
AilseVax Ltd
Christopher Scott (Advisor)
Dec 2021Activity: Consultancy types › KTP & Consultancy in kind
-
Dissecting the role of cathepsin S in dna damage repair deficient tumours.
Samantha Gallaher (Speaker), Roberta Burden (Advisor), Richard Williams (Advisor) & Christopher Scott (Advisor)
Feb 2021Activity: Talk or presentation types › Oral presentation